作者
Jeanne Tie, Joshua D Cohen, Yuxuan Wang, Michael Christie, Koen Simons, Margaret Lee, Rachel Wong, Suzanne Kosmider, Sumitra Ananda, Joseph McKendrick, Belinda Lee, Jin Hee Cho, Ian Faragher, Ian T Jones, Janine Ptak, Mary J Schaeffer, Natalie Silliman, Lisa Dobbyn, Lu Li, Cristian Tomasetti, Nicholas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, Peter Gibbs
发表日期
2019/12/1
期刊
JAMA oncology
卷号
5
期号
12
页码范围
1710-1717
出版商
American Medical Association
简介
Importance
Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurrence after completing standard adjuvant treatment cannot currently be determined. Postsurgical circulating tumor DNA (ctDNA) analysis can detect minimal residual disease and is associated with recurrence in colorectal cancers.
Objective
To determine whether serial postsurgical and postchemotherapy ctDNA analysis could provide a real-time indication of adjuvant therapy efficacy in stage III colon cancer.
Design, Setting, and Participants
This multicenter, Australian, population-based cohort biomarker study recruited 100 consecutive patients with newly diagnosed stage III colon cancer planned for 24 weeks of adjuvant chemotherapy from November 1, 2014, through May 31, 2017. Patients with another malignant neoplasm …
学术搜索中的文章
J Tie, JD Cohen, Y Wang, M Christie, K Simons, M Lee… - JAMA oncology, 2019